Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Birmingham, AlabamaAges 18 years+ - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT03211793RecruitingPhase 1/Phase 2
Cell treatment for painful hand sores in systemic sclerosis
This trial tests a cell-based treatment (mesenchymal stromal cells) to help heal painful finger/toe ulcers in people with systemic sclerosis. It is for ulcers that did not improve after a specific IV medicine called prostacyclins.
UtrechtAges 18 years+ - NCT03844061RecruitingPhase 2
Belimumab plus rituximab for early diffuse scleroderma skin disease
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
New York, New YorkAges 18–80 - NCT04356287RecruitingPhase 1/Phase 2
Cord cell treatment for severe systemic sclerosis symptoms
This early-phase study tests whether umbilical cord-derived “cord blood–type” cells can reduce or improve severe systemic sclerosis (a type of hardening/scarring disease of connective tissue). It may help people whose current standard treatments haven’t worked or caused side effects.
Montreal, QuebecAges 18 years+ - NCT04789850RecruitingPhase 2
Itacitinib for adults with diffuse systemic sclerosis
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
AmiensAges 18 years+ - NCT05016804RecruitingPhase 1
Umbilical cord stem cell infusion trial for systemic sclerosis
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
St John'sAges Any age - NCT05177380Recruiting
Personalized facial rehabilitation program for systemic sclerosis
This trial tests a personalized rehabilitation program aimed at improving facial symptoms in people with systemic sclerosis. It may help you with facial involvement while researchers measure how well the program works and is tolerated.
Strasbourg, Bas-RhinAges 18 years+ - NCT05273138Recruiting
Study of skin immune and support cells in systemic sclerosis
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
LilleAges 18 years+ - NCT05345795Recruiting
Track lung disease changes in systemic sclerosis
This study follows people with systemic sclerosis who also have lung scarring (interstitial lung disease). It aims to map how lung function and lung images change over time, which may help doctors predict and better manage disease progression.
Vandœuvre-lès-Nancy, Grand EstAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05989763Recruiting
Constipation study for people with systemic sclerosis
This study looks at why people with systemic sclerosis (a disease that can affect connective tissues) develop constipation. It will use special tests to measure how well the colon moves waste, and it may help doctors find better treatments.
Houston, TexasAges 18 years+ - NCT06051773Recruiting
Studying muscle problems in systemic sclerosis
This study is looking at how systemic sclerosis (a disease that can cause skin thickening and organ problems) affects muscles. It may help find better ways to care for patients.
NancyAges 18 years+ - NCT06058091RecruitingPhase 1/Phase 2
Cell injection therapy for systemic sclerosis
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Nanjing, JiangsuAges 18–65 - NCT06414135RecruitingPhase 1
CAR-T therapy for people with diffuse scleroderma
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
ShanghaiAges 18–65 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT06546540RecruitingPhase 4
Testing telitacicept for systemic sclerosis safety and effectiveness
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
BeijingAges 18 years+ - NCT06594302Recruiting
Function and well-being in systemic sclerosis
This trial looks at how systemic sclerosis affects daily function and mental well-being, including social and emotional factors. It may help patients understand their condition better.
Ankara, AltındağAges 18–65 - NCT06598982Recruiting
Muscle Weakness in the Breathing Muscles in Scleroderma
This study looks at whether people with systemic sclerosis (scleroderma) have weakness in the muscles they use to breathe. It aims to find out if measuring these muscles can help detect early breathing problems.
Konya, SelcukluAges 18–75 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06792344RecruitingPhase 1
CD19 CAR-T for hard-to-treat systemic sclerosis
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
Hangzhou, ZhejiangAges 5–18 - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Systemic Sclerosis trials by city
Studies with a site in or near these metro areas.
Systemic Sclerosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 175 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.